Clinical Trial Search

Primary: Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) — 23; 21 genes

Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells

Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids

Primary: Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated Versus (vs.) Untreated Side at Day 29 — -1.90; -0.12 Micro meter (µm) — p=0.0638

Primary: Skin Aging Measured With the Photonumeric Scale. — 21.25; 21.36; 21.21; 21.03 Units on a scale

Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale

Primary: Number of Genes With Significant Change in Gene Transcription — 188; 45 genes

Primary: Hydration Level — 53.19; 46.75 AU (arbitrary unit) — p=<0.05

Primary: Photographic Knee Laxity and Texture Evaluation — 1.87; 2.02 score on a scale

Primary: Analysis of Elasticity (Collagen & Elastin) — 1.7; 0.5; 1.5; 0.5 units on a scale

Primary: Blistering Time (Full Blister) — 63; 54; 65; 62 Minutes

Primary: Change From Baseline in Overall Photodamage Score — 5.6; -0.8 score on a scale — p=<0.001

Primary: Reduction of Bruising — 3.74; 4.50 cm squared

Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants

Primary: Number of Participants With Evaluator (Dermatologist) Global Assessment (EGA) Score for Well Tolerance of Product 14 Days Post-Procedure — 36; 38 Participants — p=0.3334

Primary: Change in Aesthetics — 2; 1 score on a scale

Primary: Telomere Length — 0.96; 1.06; 1.06; 1.22 ratio

Primary: VIO System Imaging Performance — 122 # participants with acceptable images

Primary: Change From Baseline in Investigator Global Assessment (IGA) of Participant's Overall Facial Appearance at Week 24 — 6.04; 5.81; 0.6; 0.7 units on scale — p=0.358

Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions

Primary: Number of Participants Reporting Product Tolerability Based on Evaluator Global Assessment Scores — 47; 44; 0; 0 Participants

Primary: Change in Epigenetic Markers — 84.4; 82.8 years

Primary: FACE-Q Satisfaction With Facial Appearance Overall Scale — 42.35; 59.42 score on a scale

Primary: Change in Microbiome — 0; 0; 0 Operational Taxonomic Unit (OTU)

Primary: Cutaneous Blood Flow Response to Local Heating of the Skin. — 68; 70 percent change in mean skin blood flow

Primary: Percent Change From Baseline in Microtopographic Profilometry Ra Values (Skin Roughness). — 3.62; 18.57 Percent change post-treatment — p=<0.0001

Primary: Change in Total Clinical Score (TCS) Between the Final Visit and Baseline — -4; -2 score on a scale

Primary: Number of Indoor Tanning Sessions in the Last 30 Days — 1.98; 1.35; 1.92 Sessions in last month

Primary: Global Photodamage Severity — 4.8; 5.45 units on a scale

Primary: Facial Skin Hydration — 56.043; 58.300; 55.852; 58.714 arbitrary units — p=1.000